Grail

Grail P/CF

The P/CF (Price-to-Cash-Flow Ratio) of Grail (GRAL) as of Oct 15, 2026 is -12.71. In the previous year, P/CF (Price-to-Cash-Flow Ratio) was -6.59 — a change of 93.02% (lower).

P/CF

-12.71

YoY

93.02%

Last updated:

P/CF (Price-to-Cash-Flow Ratio) of Grail is 2025 -12.71 . P/CF (Price-to-Cash-Flow Ratio) of Grail was 2024 -6.59 . It decreases by 93.02% lower compared to the previous year.

The Grail P/CF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/CF
Date
P/CF
Jan 1, 2018
-18.16 USD
Jan 1, 2019
-15.46 USD
Jan 1, 2020
-16.38 USD
Jan 1, 2021
-5.52 USD
Jan 1, 2022
-6.77 USD
Jan 1, 2023
-6.38 USD
Jan 1, 2024
-6.59 USD
Jan 1, 2025
-12.71 USD
The Grail P/CF history
YEARP/CFYoY
-12.71+93.02%
-6.59+3.23%
-6.38-5.79%
-6.77+22.59%
-5.52-66.29%
-16.38+5.94%
-15.46-14.86%
-18.16—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Grail Stock analysis

What does Grail do? Grail Inc, with ticker GRAL and ISIN US3847471014, is a US-based biotechnology company headquartered in Menlo Park. The company operates within the Health Care sector and has 910 employees. Grail Inc. went public on June 12, 2024. The company's website is https://www.galleri.com/. Grail Inc. focuses on early cancer detection through advanced technologies including next-generation sequencing, population-scale clinical studies, and machine learning. Its platform utilizes methylation-based approaches to support cancer screening and precision oncology, targeting multiple cancer types for early detection. The company's products include Galleri, a screening test for multi-cancer early detection, which helps guide healthcare decisions for cancer diagnosis. Grail Inc. aims to shift paradigms in cancer detection by identifying diseases at earlier stages, thereby alleviating the global burden of cancer. The company's approach integrates software, automation, and data analysis to enhance the continuum of care for cancer patients. Grail Inc. is engaged in developing solutions for cancer screening, risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring, and recurrence tracking. The company's work is centered on improving outcomes through early intervention and personalized treatment strategies. The focus on early detection aligns with efforts to reduce cancer mortality rates and improve patient survival rates globally. Grail Inc. operates with a technology-driven approach to revolutionize cancer care through innovative diagnostic tools and methodologies. Grail is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Grail stock

P/CF (Price-to-Cash-Flow Ratio) of Grail is -12.71 in 2025.

P/CF (Price-to-Cash-Flow Ratio) of Grail changed from -6.59 to -12.71, representing a 93.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/CF (Price-to-Cash-Flow Ratio) Grail since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Cash-Flow ratio measures the stock price relative to operating cash flow per share. Unlike P/E, it is harder to manipulate as cash flow is less subject to accounting adjustments.

P/CF = Stock Price / Operating Cash Flow per Share

To evaluate P/CF (Price-to-Cash-Flow Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/CF (Price-to-Cash-Flow Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/CF (Price-to-Cash-Flow Ratio)'s Grail with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Grail

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Grail